Press Releases

June 25, 2019

Nymox End of Q2 New Investor Presentation on Website

Nymox Pharmaceutical Corporation is pleased to provide an up-to-date investor communication presentation posted on the Nymox website today as the end of second quarter update for shareholders. 

Download
April 16, 2019

Nymox Reports Pre-NDA CMC Meeting with the FDA

Nymox Pharmaceutical Corporation today announced that it has held its pre-New Drug Application (NDA) Chemistry Manufacturing and Controls (CMC) meeting with the US Food and Drug Administration (FDA) regarding its lead product candidate Fexapotide Triflutate.

Download
March 21, 2019

Nymox Teleconference Monday, March 25 10:00 a.m. EDT

Nymox will hold a teleconference for shareholders on Monday, March 25 at 10:00 a.m. Eastern Daylight Time (EDT). Management will provide an update on the current status of the Company's business activities including regulatory filings, and after the update will respond to calls from shareholders and interested parties.

Download
March 19, 2019

Nymox Announces Appointment of Mark Staples PhD as Vice President of Chemistry, Manufacturing and Controls (CMC)

Nymox Pharmaceutical Corporation is pleased to announce that Mark Staples PhD has joined Nymox as Vice President for Chemistry, Manufacturing, and Controls (CMC).

Download
March 13, 2019

Nymox Announces Appointment of Russell Thomson Ph.D. as Director of Quality and EU Qualified Person for Company's Manufacturing Operations

Nymox Pharmaceutical Corporation is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC, as the Company's Director of Quality and EU Qualified Person, for all of Nymox's Chemistry, Manufacturing and Controls Operations.

Download
March 11, 2019

Nymox to Host Investor Teleconference

Management will discuss the Company's current business progress with an update on its regulatory submission activities in the US and EU. Further details re time and coordinates and information for the call will be provided prior to the teleconference.

Download
January 15, 2019

New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology

Nymox Pharmaceutical Corporation reports today that a new peer review article has been published in Therapeutic Advances in Urology.

Download
December 19, 2018

2018: A Year of Achievements for NYMOX

Following the Nymox Annual General Meeting yesterday (December 18, 2018), Nymox management discussed many significant 2018 events and commented on key operational milestones coming up in 2019.

Download
October 11, 2018

Corporate Update To Shareholders: Preparatory Work For Regulatory Filings On Track

Following many shareholder enquiries in recent weeks Nymox Pharmaceutical Corporation is pleased to provide shareholders with a brief update on its core activities.

Download
October 9, 2018

Nymox Reports 78 Month Results From Biopsy and Surgery Confirmed Prospective Randomized NX03-0040 Prostate Cancer Study of Fexapotide Triflutate: Gleason Grade Progression Reduced by 81% Overall and Fexapotide 15mg Minimal Treatment Leads to 73% Long-Term Reduction in Incidence of Associated Prostate Cancer Surgery and Radiotherapy

Nymox Pharmaceutical Corporation is pleased to announce today important new long-term clinical trial results from the Company’s 146 patient Phase IIb NX03-0040 Fexapotide (FT) U.S. study for low grade localized prostate cancer.

Download
October 3, 2018

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia

Nymox Pharmaceutical Corporation reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.

Download
July 2, 2018

Nymox Announces Expanded Marketing Plans

Nymox Pharmaceutical Corporation announced today that following the recently announced increased manufacturing capabilities, the Company has formally decided to expand its European marketing plans for Fexapotide Triflutate (FT) to all countries in the European Community.

Download
June 7, 2018

NYMOX Successfully Achieves Manufacturing Scale-Up

Nymox Pharmaceutical Corporation is pleased to report that manufacturing scale-up milestones have been reached for the Company’s lead compound Fexapotide Triflutate (FT).

Download
May 22, 2018

Fexapotide Triflutate Pivotal Phase 3 Study Results Presented and Discussed at American Urological Association Annual Meeting in San Francisco

Nymox Pharmaceutical Corporation is pleased to report on a successful symposium discussing Nymox’s lead product candidate Fexapotide Triflutate (FT) as a novel therapeutic option in BPH at the Annual Meeting of the American Urological Association in San Francisco, this past weekend.

Download
May 11, 2018

Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology

Nymox Pharmaceutical Corporation is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology, a highly respected and authoritative urologic professional community, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions.

Download
May 7, 2018

Nymox Announces Relocation of Company Headquarters to Switzerland

Nymox Pharmaceutical Corporation is pleased to announce that it has initiated the process of relocating the Company Headquarters from Nassau, Bahamas to Zug in Switzerland.

Download
May 2, 2018

Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco ‎May 20

Nymox Pharmaceutical Corporation is pleased to announce that there will be a Symposium on the Company’s lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco.

Download
April 12, 2018

Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors

Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional high net worth investors.

Download
April 10, 2018

New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology

A new online published commentary about Nymox’s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday in its “Beyond the Abstract” section, along with the abstract of the World Journal of Urology article.

Download
March 1, 2018

Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association Mid-Atlantic Section, in Amelia Island FL March 3.

Download
February 5, 2018

Nymox Announces US NDA for Fexapotide for BPH

Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.

Download
January 30, 2018

Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

Nymox Pharmaceutical Corporation reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.

Download
January 22, 2018

Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men

Nymox Pharmaceutical Corporation reported today top-line 5-year results from Nymox’s U.S. Study NX03-0040. Study NX03-0040 was undertaken starting in 2012 at 44 investigational sites across the U.S. comprising a highly representative sample of 146 men with the biopsy confirmed diagnosis of T1c prostate cancer, which is the most common type of low grade localized prostate cancer.

Download
November 27, 2017

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27.

Download
November 16, 2017

Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15

Download
November 10, 2017

Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week.

Download
November 7, 2017

Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana

Nymox Pharmaceutical Corporation is pleased to report on the two data presentations which were held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, New York Section in Havana, November 6.

Download
October 26, 2017

Nymox Announces Two Data Presentations for Company’s BPH Drug at New York American Urological Association Meeting November 6

Nymox Pharmaceutical Corporation is pleased to announce that two data presentations of the Company’s new drug Fexapotide Triflutate will be held at the November meeting of the American Urological Association, New York Section.

Download
October 13, 2017

Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, Northeast Section in Savannah, October 12 at 4 pm.

Download
October 10, 2017

Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12

Nymox Pharmaceutical Corporation is pleased to report on the Symposium on Fexapotide Triflutate studies to be held at the Annual Meeting of the American Urological Association Northeastern Section, in Savannah GA this week.

Download
September 25, 2017

Nymox Announces October 12 Symposium for Company’s BPH Drug at American Urological Association Meeting

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the October meeting of the American Urological Association, Northeast Section.

Download
September 14, 2017

Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox’s Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.

Download
September 11, 2017

AUA Meeting in Florida September 16 Postponed Due to Hurricane

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.

Download
August 9, 2017

Nymox Announces Private Placements of $3 Million

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million.

Download
August 7, 2017

Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September

Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, MidAtlantic Section.

Download
May 31, 2017

Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials

Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Companys prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Companys U.S. long-term clinical trials.

Download
May 10, 2017

NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT

Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).

Download
May 8, 2017

NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT

Following Nymoxs announcement of the Companys filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EST on Wednesday May 10, 2017.

Download
May 3, 2017

Nymox Files For Marketing Approval For Fexapotide Triflutate in Europe

May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.

Download
March 29, 2017

Nymox Provides Update on Fexapotide Development

Nymox Pharmaceutical Corporation provided an update today on the Companys development activities for Fexapotide Triflutate, its new drug for prostate enlargement.

Download
November 29, 2016

Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.

Download
October 11, 2016

Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

Download
August 29, 2016

Nymox’s New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers…

Download
August 24, 2016

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Companys lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

Download
August 17, 2016

Nymox Announces Private Placements of $2.24 Million

Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.

Download
August 11, 2016

Nymox Announces Prostate Drug Progress

Nymox Pharmaceutical Corporation is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Companys Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.

Download
June 22, 2016

Nymox Reports Long-Term Prostate Cancer Results in 7 Year Prospective Study of 995 U.S. Middle-Aged and Elderly Men Without Cancer

Nymox Pharmaceutical Corporation announced today results from the Companys 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Companys lead drug fexapotide.

Download
February 9, 2016

Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study

Nymox Pharmaceutical Corporation today announced results from the completion of the Companys U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207).

Download
February 4, 2016

Nymox Announces Additional $2.1 Million Equity Financing

Nymox Pharmaceutical Corporation announced today private placement equity investment of US$2.1 Million.

Download
December 17, 2015

Nymox Files Current Financial Statements

Nymox Pharmaceutical Corporation is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements.

Download
December 17, 2015

Nymox Provides Update From Shareholders Annual General Meeting December 16

Nymox Pharmaceutical Corporation is pleased to report an update on the Corporations business as of December 16, 2015.

Download
October 29, 2015

Nymox Reports Results of Prospective Cross-Over Study of Fexapotide Treatment for Prostate Cancer

Nymox Pharmaceutical Corporation reported today that long-term randomized cross-over data from the Companys trial of fexapotide triflutate for low grade localized prostate cancer has shown statistical significance in efficacy compared to controls.

Download
August 4, 2015

Nymox Announces Change of Company’s Domicile and Head Office

Nymox Pharmaceutical Corporation is pleased to announce that the Company has received formal approvals for its change of domicile to the Bahamas effective July 31, 2015.

Download
July 30, 2015

Nymox Announces Appointment of James G. Robinson to Board of Directors

Nymox Pharmaceutical Corporation is pleased to announce that the Company has newly appointed James G. Robinson to the Board of Directors.

Download
July 28, 2015

Nymox July 27 Webcast of New BPH Clinical Trial Results Posted Today Online

(July 28, 2015) Nymox’s (NASDAQ:NYMX) July 27th webcast of news and discussion by experts of the Company’s new clinical trial results can be viewed at http://limelightdc.com/clientarea/nymox_investor_webcast_7_15/player_vod.html. The link is also available at the Company’s website.

Download
July 27, 2015

Nymox Pivotal Phase 3 NX-1207 BPH Extension Trial Successfully Meets Primary Endpoint. Company Plans to File For Regulatory Approvals For Fexapotide Triflutate (NX-1207).

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Companys U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo.

Download
July 16, 2015

Nymox Appoints Cutler & Co. as Auditor

July 16, 2015: On July 15, 2015, the Board of Directors of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) approved the engagement of Cutler & Co., LLC to serve as the Company’s new independent registered public accounting firm to replace KPMGLLP.

Download
July 13, 2015

Nymox Announces Appointment of Erik Danielsen as CFO

Nymox Pharmaceutical Corporation is pleased to announce the appointment of Erik Danielsen as Chief Financial Officer of the Company.

Download
June 16, 2015

Nymox Announces $850,000 Financing

Nymox Pharmaceutical Corporation is pleased to announce that it has recently completed financing for a total of $850,000 at prices of $1.25-$1.66.

Download
May 15, 2015

Nymox Reports First Quarter 2015 Financial Results

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.

Download
April 20, 2015

Nymox Announces New Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical Corporation announced today long-term clinical trial results from the Companys NX-1207 prostate cancer study NX03-0040.

Download
April 1, 2015

Nymox Announces Phase 3 BPH Studies

Nymox Pharmaceutical Corporation announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).

Download
March 31, 2015

Nymox Reports 2014 Financial Results

March 31, 2015: Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2014 prepared in accordance with International Financial Reporting Standards.

Download
March 19, 2015

Nymox Announces Private Placements of US $400,000

March 19, 2015: Nymox Pharmaceutical Corporation announced today recent private placements of 883,058 shares, with total proceeds of US$400,000.

Download
December 14, 2014

Nymox Announces $1.07 Million Financing

December 18, 2014: Nymox Pharmaceutical Corporation announced today the closing of U.S. $1.07 million in financing, consisting of a 3 year term convertible debenture at 6% with conversion at $0.53.

Download
November 14, 2014

Nymox Reports Third Quarter 2014 Financial Results

November 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the third quarter of 2014.

Download
November 2, 2014

Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02- 0018 Fail to Meet Primary Efficacy Endpoints

November 2, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company’s two Phase 3 U.S. studies of NX-1207 for the treatment of BPH, NX02-0017 and NX02-0018, failed to meet their primary efficacy endpoints.

Download
September 11, 2014

Nymox Reports Second Quarter 2014 Financial Results

August 11, 2014: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today its financial results for the second quarter of 2014.

Download
September 10, 2014

Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results

September 10, 2014: Nymox announced today new positive outcome results from the Companys ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer.

Download
July 22, 2014

Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

Download
July 15, 2014

Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study

Download
June 17, 2014

Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

June 17, 2014: Nymox is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Companys lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia) and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments.

Download
June 11, 2014

Nymox Reports Positive New Safety Study Data For Phase 3 BPH Drug

June 11, 2014: Nymox is pleased to announce new clinical data supporting the positive safety profile of NX-1207, the Companys lead compound in late Phase 3 testing for prostate enlargement (BPH or benign prostate hyperplasia). Recent pharmacokinetic studies using a newly developed highly sensitive blood test for NX-1207 have shown that the drug is undetectable in the blood post-injection, providing strong evidence that the drug, once injected into the prostate, remains confined to the prostate and thus unable to affect other organs such as the liver, kidneys, heart, or testes.

Download
May 21, 2014

Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment

May 21, 2014: Nymox is pleased to report new positive data confirming the advantageous side effect profile of the Companys lead compound NX-1207. Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Companys recently completed NX03-0040 trial of NX-1207 2.5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.

Download
May 15, 2014

Nymox Reports First Quarter 2014 Financial Results

May 15, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2014.

Download
May 13, 2014

Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels

Download
May 8, 2014

Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH

Download
May 6, 2014

Nymox Announces Positive New Prostate Cancer Clinical Trial Results

Download
April 30, 2014

Nymox Reports Top-Line Results for Localized Prostate Cancer Study

April 30, 2014: Nymox is pleased to report top-line results from the companys 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study.

Download
March 14, 2014

Nymox Reports 2013 Financial Results

March 14, 2014: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the year ended December 31, 2013.

Download
February 5, 2014

Nymox Announces Appointment of Andre Monette

February 5, 2014: Nymox is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company.

Download
January 28, 2014

Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities

Download
January 13, 2014

Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial

January 13, 2014: Nymox today announced that recruitment is being closed for the Companys Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.

Download